GLP-1 medications reduced the risk of major adverse cardiovascular events by 13% compared to a placebo, according to a study published Nov. 25 in The Lancet Diabetes & Endocrinology.
The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.